Because retatrutide remains in the clinical trial phase, comprehensive real-world data on the prevalence of sleep disturbances are not yet available
To view a copy of this licence, visit About this article Cite this article Movahednasab, M., Dianat-Moghadam, H., Khodadad, S
The human data reflects this advantage, with retatrutide achieving 24.2% weight loss at 48 weeks compared to tirzepatide reaching approximately 21% at 72 weeks in the SURMOUNT trials
Large or heavy meals can overwhelm your digestive system
Some participants achieved weight loss of approximately 24% of body weight at 48 weeks approaching levels reported with some bariatric surgical procedures, though no direct head-to-head comparisons have been conducted and long-term durability beyond the trial period remains unknown